文献速递头颈与中枢神经肿瘤胸部肿瘤

基因表达谱识别的免疫活跃表型与真实世界头颈癌和肺癌患者PD-1/PD-L1抑制剂临床获益相关

Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1/PD-L1 inhibitors in real-world head and neck and lung cancer patients.
PubMed 文献 · Eur J Cancer · 2022-08-26

研究利用421例头颈鳞癌(HNSCC)基因表达谱建立27基因HOT评分,并在40例HNSCC与992例NSCLC中验证,另在76例配对样本中检验稳定性;在184例接受PD-1/PD-L1抑制剂治疗的患者中,HOT评分在多因素分析中与总生存(OS)和无进展生存(PFS)改善相关。

要点

  • HOT评分基于27个基因的表达,与PD-L1、IDO1表达、CD8 T细胞浸润及IFN-γ通路激活相关。
  • 诊断活检与手术切除标本的HOT评分一致性高于未治疗与复发样本、西妥昔单抗治疗前后样本。
  • 在102例HNSCC和82例NSCLC患者中,HOT评分在多因素分析中与OS和PFS改善相关。

核心结论

  • HOT评分是一种简单、稳健的方法,可用于识别真实世界中免疫活跃肿瘤的HNSCC和NSCLC患者,这些患者可能从PD-1/PD-L1抑制剂中获益。

研究设计与样本

  • 利用421例HNSCC的基因表达谱开发识别免疫活跃肿瘤的评分,并在40例HNSCC和992例NSCLC中验证HOT评分。
  • 在共76例患者中,用配对HNSCC样本检验HOT评分的稳定性,包括诊断活检与手术切除标本、未治疗与复发样本、西妥昔单抗治疗前后样本。
  • 在184例接受PD-1/PD-L1抑制剂治疗的HNSCC或NSCLC患者中,检验HOT评分与OS和PFS的关联。

主要发现

  • 基于27个基因表达的HOT评分与PD-L1和IDO1表达、CD8 T细胞浸润及IFN-γ通路激活相关。
  • HOT评分在诊断活检与手术切除标本之间的一致性,高于未治疗样本与复发样本之间以及西妥昔单抗治疗前后样本之间的一致性。
  • 在102例HNSCC和82例NSCLC接受PD-1/PD-L1抑制剂治疗的患者中,HOT评分在多因素分析中与OS和PFS改善相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Identification of tumours harbouring an overall active immune phenotype may help for selecting patients with advanced head and neck squamous cell carcinomas (HNSCC) and non-small cell lung cancer (NSCLC) who may benefit from immunotherapies. Our objective was to develop a reliable and stable scoring system to identify those immunologically active tumours. METHODS: Using gene expression profiles of 421 HNSCC, we developed a score to identify immunologically active tumours. Validation of the 'HOT' score was done in 40 HNSCC and 992 NSCLC. Stability of the 'HOT' score was tested in paired HNSCC samples from diagnostic biopsies versus surgically resected specimens, untreated versus recurrent samples, and pre-versus post-cetuximab samples in a total of 76 patients. The association between the 'HOT' score with overall survival (OS) and progression-free survival (PFS) was tested in 184 patients with HNSCC or NSCLC treated with PD-1/PD-L1 inhibitors. RESULTS: A 27-gene expression based 'HOT' score was correlated with: (i) PD-L1 and IDO1 expression, (ii) TCD8 infiltrate and (iii) activation of the IFN-γ pathway. The HOT score concordance when comparing diagnostic biopsies and surgically resected specimens was higher than in untreated samples versus recurrent or pre-versus post-cetuximab samples. In 102 and 82 patients with HNSCC or NSCLC treated with PD-1/PD-L1 inhibitors, the HOT score was associated with an improved OS and PFS in multivariate analysis. CONCLUSION: The 'HOT' score is a simple and robust approach to identify real-world patients with HNSCC and NSCLC immunologically active tumours who may benefit from PD-1/PD-L1 inhibitors.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Foy JP, Karabajakian A, Ortiz-Cuaran S, et al. Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1/PD-L1 inhibitors in real-world head and neck and lung cancer patients. Eur J Cancer. 2022. PMID: 36038492. doi:10.1016/j.ejca.2022.06.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。